Phase 2RecruitingPriority 3 · Moderate priorityNCT05963347
Go-CHOP as the Frontline Therapy for PTCL
Plain-language summary
This Phase 2 trial is evaluating Golidocitinib and CHOP Regimen as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.
Who can join (key eligibility)
- Age 18 Years or older
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Golidocitinib (DRUG): Daily dose. Starting dose of golidocitinib is 75 mg QD. If tolerated, subsequent cohorts will test ascending doses of golidocitinib. | CHOP Regimen (DRUG): CHOP will be administered in a 21-day cycle for a maximum of 6 cycles.
- Drugs / treatments
- Golidocitinib, CHOP Regimen
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details